European Court of Justice advocate general Yves Bot has sought to offer clarification for the granting of supplementary protection certificates in European Union accession countries1,2. In his opinion on Kirin Amgen v State Patent Bureau of the Republic of Lithuania, the advocate general concluded that a patent holder of a centrally authorised medicinal product is prohibited from obtaining an SPC post-accession in Lithuania...
Please login to read the full article.Welcome:
IBI01 - Circulation
scr
RAJ Pharma
SPCs in EU accession states must be backed by national authorisations
13 April 2010
Faraz Kermani
RELATED CONTENT
NEWS
RAJ Pharma News
Other Informa News
ANALYSIS
Other Informa Analysis
EDITORIALS
Other Informa Editorials
FEATURES
RAJ Pharma Features
Other Informa Features
COUNTRY PROFILES
RAJ Pharma Country Profiles
Other Informa Country Profiles
COMMENT
RAJ Pharma Comment
Other Informa Comments
EVENTS
October 4th, 2010
London, UK
October 19th, 2010
Barcelona, Spain
October 20th, 2010
Barcelona, Spain